Portfolio Simplification and Deferred Vaccine Business Spin-Off

CSL is pursuing a strategy to simplify its complex, modality-based portfolio and has decided to temporarily defer the planned spin-off of its vaccine business, Seqirus. This decision was driven by an analytical assessment to protect shareholder value, given that influenza vaccination rates in the U.S. have fallen significantly below expectations, and to wait for market conditions to improve. The vaccine division urgently needed to manage its risks, as KOSTAIVE, a saRNA-based COVID-19 vaccine, received European approval in 2025 but was halted due to false-positive HIV diagnostic issues, resulting in a $566 million asset impairment. Consequently, CSL shifted its focus from immediately separating the vaccine business to first stabilizing it and streamlining its internal modalities.

Limitations of Diversification Through Vifor Acquisition and Focus on Nephrology

CSL's acquisition of Vifor Pharma in 2021 for $11.7 billion was a key diversification strategy aimed at expanding the company's plasma and vaccine-centric business into nephrology and renal diseases. CSL Vifor achieved $1.2 billion in revenue in the first half of 2026, a 12% increase year-over-year, becoming a major growth driver for the company. However, it faced challenges in its core iron deficiency treatment market due to generic competition, resulting in a 15% decline in sales. As a result, CSL is reallocating resources from defending its iron treatment business to focus on areas with high unmet medical needs, such as chronic kidney disease (CKD) and cardio-renal diseases. The inclusion of Velphoro in the U.S. formulary, leading to a 40% increase in dialysis nephrology sales, and the European launch of Tavneos and Filspari exemplify this strategic shift.

$2.2 Billion VarmX Option Deal and Flexible BD Strategy

CSL is transitioning from large-scale mergers and acquisitions (M&A) to a more flexible business development (BD) strategy that leverages option agreements and licensing. A prime example is the agreement with Dutch biotech VarmX, which grants CSL the option to acquire the company after reviewing Phase 3 data for VMX-C001, a Factor Xa DOAC reversal agent. CSL paid an upfront payment of $117 million to secure the option and will make milestone payments of up to $2.2 billion, depending on future clinical and regulatory milestones. This deal structure is considered a sophisticated venture capital (VC)-style approach, designed to mitigate risk and financial burden by deferring a large upfront investment until the data is validated and the final investment decision is made.

Pipeline Commercialization Success and Lilly Licensing Agreement

CSL is leveraging its strong historical expertise in hematology and rare diseases to support the successful market launch of garadacimab (brand name ANDEMBRY) and HEMGENIX. ANDEMBRY, which received FDA approval in June 2025, demonstrated overwhelming efficacy in clinical trials, reducing the number of attacks by more than 99%, and HEMGENIX complements the company's existing plasma-derived factor business as a one-time gene therapy. Meanwhile, CSL entered into an agreement with Eli Lilly to transfer the development rights for clazakizumab for non-renal indications in exchange for a $100 million upfront payment, while retaining exclusive rights to kidney-targeted therapies. This further demonstrates CSL's strategy of focusing resources on key rare disease areas and maximizing opportunities in other markets through partnerships, reflecting a highly pragmatic approach to portfolio simplification.